Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Enzyme Replacement Therapy Market
Enzyme Replacement Therapy (ERT) Market size was valued to be USD 9.3 billion in 2022 and is expected to reach USD 18.6 billion in 2032 with a CAGR of 7.1% by 2032 due to the rising prevalence of rare genetic disorders, including LSDs such as gaucher disease, fabry disease, pompe disease, and mucopolysaccharidosis (MPS).
According to research conducted by Rare diseases International in 2022, rare diseases currently affect 3.5% to 5.9% of the global population at any given time, which is equivalent to around 300 million individuals globally. Increasing advancements in research and development of new enzyme replacement therapies and next-generation treatments has expanded treatment options for patients and increasing access to therapies in regions with previously limited availability.
Moreover, early diagnosis of Lysosomal storage diseases (LSDs) and other enzyme deficiencies through prenatal and newborn genetic testing has allowed for the timely initiation of ERT. Early treatment is associated with better clinical outcomes, leading to increased demand for ERT. Also, advances in biotechnology and precision medicine have led to the development of more targeted and effective ERTs.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Enzyme Replacement Therapy Market Size in 2023: | USD 9.97 billion |
Forecast Period: | 2024 to 2032 |
Forecast Period 2024 to 2032 CAGR: | 7.2% |
2032 Value Projection: | USD 18.6 Billion |
Historical Data for: | 2018 to 2023 |
No. of Pages: | 197 |
Tables, Charts & Figures: | 345 |
Growth Drivers: |
|
Pitfalls & Challenges: |
|